The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations

American Journal of Hypertension
H R Brunner

Abstract

This article reviews the pharmacokinetics and pharmacodynamics of angiotensin II (AII) receptor antagonists (AIIRA), with particular focus on the novel compound irbesartan. Irbesartan has the highest oral bioavailability in its class (60% to 80%) and, unlike valsartan, its absorption is not affected by food. Irbesartan displays linear, dose related pharmacokinetics and, with the exception of tasosartan's active metabolite, has the longest elimination half-life of the AIIRA (11 to 15 h). Irbesartan exhibits the lowest amount of protein binding, limiting its potential for drug interactions. No drug interactions with irbesartan have been identified. Unlike losartan, candesartan, and tasosartan, irbesartan does not require biotransformation for AII blockade. The pharmacokinetics of irbesartan are not altered in renally or hepatically impaired patients, probably owing to excretion characteristic by both biliary and renal routes, or by differences in gender or age. Within its therapeutic dose range (150 to 300 mg), irbesartan shows sustained, dose related blockade 24 h after dosing. Irbesartan lowers blood pressure in a dose related manner up to 300 mg daily. Some clear differences in pharmacokinetics and pharmacodynamics exist among...Continue Reading

Citations

Oct 31, 2001·Blood Pressure. Supplement·T Unger
Feb 16, 2005·Expert Opinion on Drug Safety·Steffen BöhlerWilhelm Kirch
Mar 5, 2017·Cardiology and Therapy·Xiaoshen ZhangMichael R Hamblin
Jun 4, 1999·Journal of Clinical Pharmacology·M M McConnaugheyA J Ingenito
Jul 28, 1999·Clinical and Experimental Hypertension : CHE·A MimranG DuCailar
Jul 24, 2001·Blood Pressure. Supplement·G Mancia
Jul 27, 2010·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Carlos Eduardo de Matos JensenRubén Dario Sinisterra
Aug 12, 2005·European Journal of Clinical Pharmacology·Xiumei HongXiping Xu
Jul 1, 2008·Future Cardiology·Christoph Schindler, Carlos M Ferrario
Dec 15, 2015·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Ryo WatanabeMitsuaki Isobe
Jun 20, 2002·Journal of Cardiovascular Pharmacology·Maria R Marino, Nimish N Vachharajani
May 10, 2011·Drug Development and Industrial Pharmacy·Zhi-Liang ZhangJian-Feng Chen
Jun 24, 2004·British Journal of Pharmacology·Shu-Meng ChengJenn-Haung Lai
Nov 27, 2004·Pharmacology·Christian HöchtCarlos A Taira
Nov 25, 2014·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Hazel Mae A AbrahamWilliam B White
Mar 5, 2003·Advances in Renal Replacement Therapy·Kathryn Sandberg, Hong Ji
May 31, 2019·Organic Letters·Attila SveiczerDavid R Spring
Dec 15, 2020·The Journal of Organic Chemistry·Pallavi SharmaTeresa G Carvalho
May 30, 2003·Journal of Medicinal Chemistry·Boris Schmidt, Bernhard Schieffer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.